JNJ - Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation- positive lung cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.